Life Science Leader

Scaling Biologics: Strategies for Enhancing Bioprocessing Productivity 🗓 October 27, 2025 | 11:00am ET As biologics grow more complex, efficient scale-up and cost control are critical. Join Meeta Gulyani, SVP & GM, Bioprocessing at Ecolab Life Sciences, for an executive discussion on strategies to boost productivity and manage costs in today’s biopharma landscape. Discover how innovative resin technologies and process optimization can accelerate your path from development to patients. 🔗 Reserve your seat: https://lnkd.in/efEUDtMb

The Moral Economics Of Precision Medicine So here we are, faced with the age-old dilemma of ROI vs. ethics. To quote Robert Tressler of Excellos, “we are in healthcare, not moneycare.” https://lnkd.in/etrJDkTs

The Moral Economics Of Precision Medicine Unlike past breakthroughs, these novel and promising therapies are burdened by realities of cost and scale (and return on investment) that are orders of magnitude more difficult to fit into the traditional blockbuster model. By Kat Kozyrytska and Ryan Murray https://lnkd.in/eWU-6aEc

Why I Love Working With Leaders Who Have 'Rounded Corners' “Rounded corner leaders are not soft or indecisive. They have a core of steel, but their strength is tempered with compassion and humility.” - Dr. Tara Miller, DBA https://lnkd.in/eTKdpVrS

September on Business of Biotech This month’s conversations explored the “biostack” approach to life sciences investing, new uses for drug conjugates, cannabinoids, and psychedelics, and how HEOR can strengthen early-stage biotech strategies.

Reading The FDA Tea Leaves On Psychedelics By Ben Comer, Chief Editor, Life Science Leader After nearly a decade of negotiation with the FDA, Rick Doblin, founder of Multidisciplinary Association for Psychedelic Studies (MAPS), says the agency “changed the goal post” in its review of MDMA-assisted therapy for PTSD. Despite years of collaboration on trial design — including strategies to address the unique challenges of double-blinding psychedelics — the FDA ultimately declined approval for Lykos Therapeutics’ midomafetamine program, reigniting debate over how regulators will evaluate this emerging class of therapies. https://lnkd.in/erfqKQv5

How The New Biotech Market Is Redefining Leadership By Jeff Walsh Biopharma’s boldest breakthroughs come with a hidden cost: inventing the playbook as you go. Today’s leaders must not only pioneer new therapies but also build the regulatory and commercial paths to sustain them — all while facing tighter capital and higher expectations for proof and payoff. https://lnkd.in/ehMmWddC

Biopharma leaders face a defining challenge: how to scale increasingly complex biologics efficiently—without letting downstream costs consume the pipeline. The old “one size fits all” playbook no longer applies. Join Meeta Gulyani, SVP & GM of Bioprocessing at Ecolab Life Sciences, on October 27 at 11:00 AM ET for a forward-looking discussion on strategies driving the next generation of bioprocessing productivity. Discover how innovation in resin technologies and process optimization is helping organizations bring breakthrough therapies to patients faster—while staying competitive in an evolving market. Register here: https://lnkd.in/gq2RdKDK #webinar #bioprocessing #innovation

100% Drug Tariffs Are A Dire Threat — And Patients Can't Wait “We cannot afford to sit idle. We must act now — working with federal and state policymakers to prevent the harmful consequences of these proposed tariffs.” — Debbie Hart, President & CEO, BioNJ A 100% tariff on select prescription drugs isn’t just a policy threat — it’s a potential breaking point for patients, innovation, and America’s life sciences ecosystem. Hart warns that the costs could cascade from manufacturers to patients, driving up prices, disrupting R&D, and undoing years of progress in drug access and supply stability. This isn’t just about economics — it’s about ensuring patients aren’t left behind. Read the full perspective: https://lnkd.in/e22tpkZK

In radiopharma, knowing what you do best is a competitive advantage. As Ebrahim Delpassand, M.D. of Radiomedix, Inc. puts it: “Developing a drug is one thing, but navigating insurance companies, contracting, and manufacturing for commercial launch … it’s a totally different ballgame.” Partnering withCurium Pharmaa allowed RadioMedix to turn scientific innovation into market success — and capture over 70% of the market for Detectnet, the first FDA-approved copper-64 diagnostic. For emerging biotechs in radiopharmaceuticals, commercial strategy isn’t an afterthought — it’s the bridge between discovery and patient impact. https://lnkd.in/eCv__Zpv